Literature DB >> 8697299

Insulin-secreting cell lines: classification, characteristics and potential applications.

V Poitout1, L K Olson, R P Robertson.   

Abstract

The use of primary beta-cells in biochemical and molecular research is limited by the availability of pancreatic endocrine tissue. Numerous investigators have attempted to establish an insulin-secreting cell line that retains normal regulation of insulin secretion. Different approaches have been used, including induction of pancreatic tumors by irradiation or viral infection, immortalization of beta-cells in vitro, and development of transgenic mice with targeted expression of a recombinant oncogene in the beta-cell. Few of these attempts have proven successful, because cell differentiation and proliferation capacities are mutually exclusive. The most widely used insulin-secreting cell lines are RIN, HIT, beta TC, MIN6 and INS-1 cells. These cells contain mainly insulin and small amounts of glucagon and somatostatin. RIN cells, except for the subclone RIN-38, are not glucose-responsive. HIT cells and beta TC cells secrete insulin in response to glucose, but their dose-response curve is markedly shifted to the left MIN6, INS-1 and a newly available subclone of beta TC cells (beta TC-6 F7) are reported to retain normal regulation of glucose-induced insulin secretion. Although the behaviour of none of these cell lines perfectly mimics primary beta-cell physiology, they are extremely valuable tools for the study of molecular events underlying beta-cell function and dysfunction. In addition, insulin-secreting cell lines represent a potential source of transplantable tissue to overcome the limited availability of primary islets for this procedure.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8697299

Source DB:  PubMed          Journal:  Diabetes Metab        ISSN: 1262-3636            Impact factor:   6.041


  26 in total

1.  The Nkx6.1 homeodomain transcription factor suppresses glucagon expression and regulates glucose-stimulated insulin secretion in islet beta cells.

Authors:  Jonathan C Schisler; Per Bo Jensen; David G Taylor; Thomas C Becker; Filip Krag Knop; Shiro Takekawa; Michael German; Gordon C Weir; Danhong Lu; Raghavendra G Mirmira; Christopher B Newgard
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-09       Impact factor: 11.205

2.  Antihyperglycemic profile of erinidine isolated from Hunteria umbellata seed.

Authors:  Adewale Adeneye Adejuwon; Peter Anthony Crooks; Zaineb Fadhel-Albayati; Anne-Frances Miller; S Williams Zito; Olufunmilayo Olaide Adeyemi; Esther Oluwatoyin Agbaje
Journal:  Afr J Tradit Complement Altern Med       Date:  2012-12-31

3.  Mimicking Neuroligin-2 Functions in β-Cells by Functionalized Nanoparticles as a Novel Approach for Antidiabetic Therapy.

Authors:  Anna Munder; Liron L Israel; Shirin Kahremany; Rina Ben-Shabat-Binyamini; Charles Zhang; Michal Kolitz-Domb; Olga Viskind; Anna Levine; Hanoch Senderowitz; Steven Chessler; Jean-Paul Lellouche; Arie Gruzman
Journal:  ACS Appl Mater Interfaces       Date:  2017-01-03       Impact factor: 9.229

4.  An AP-3-dependent mechanism drives synaptic-like microvesicle biogenesis in pancreatic islet beta-cells.

Authors:  Arthur T Suckow; Branch Craige; Victor Faundez; William J Cain; Steven D Chessler
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-05-04       Impact factor: 4.310

5.  The level of menadione redox-cycling in pancreatic β-cells is proportional to the glucose concentration: role of NADH and consequences for insulin secretion.

Authors:  Emma Heart; Meridith Palo; Trayce Womack; Peter J S Smith; Joshua P Gray
Journal:  Toxicol Appl Pharmacol       Date:  2011-11-15       Impact factor: 4.219

6.  TRPM5 regulates glucose-stimulated insulin secretion.

Authors:  Lili R Brixel; Mahealani K Monteilh-Zoller; Claudia S Ingenbrandt; Andrea Fleig; Reinhold Penner; Thorsten Enklaar; Bernhard U Zabel; Dirk Prawitt
Journal:  Pflugers Arch       Date:  2010-06       Impact factor: 3.657

7.  In vitro mechanism of action on insulin release of S-22068, a new putative antidiabetic compound.

Authors:  L Le Brigand; A Virsolvy; D Manechez; J J Godfroid; B Guardiola-Lemaître; F M Gribble; F M Ashcroft; D Bataille
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

8.  Studies of phospholipid metabolism, proliferation, and secretion of stably transfected insulinoma cells that overexpress group VIA phospholipase A2.

Authors:  Z Ma; A Bohrer; M Wohltmann; S Ramanadham; F F Hsu; J Turk
Journal:  Lipids       Date:  2001-07       Impact factor: 1.880

9.  Efficient gene delivery and silencing of mouse and human pancreatic islets.

Authors:  Bruno Lefebvre; Brigitte Vandewalle; Justine Longue; Ericka Moerman; Bruno Lukowiak; Valery Gmyr; Kathrin Maedler; Julie Kerr-conte; François Pattou
Journal:  BMC Biotechnol       Date:  2010-03-30       Impact factor: 2.563

10.  Pancreatic islets and insulinoma cells express a novel isoform of group VIA phospholipase A2 (iPLA2 beta) that participates in glucose-stimulated insulin secretion and is not produced by alternate splicing of the iPLA2 beta transcript.

Authors:  Sasanka Ramanadham; Haowei Song; Fong-Fu Hsu; Sheng Zhang; Mark Crankshaw; Gregory A Grant; Christopher B Newgard; Shunzhong Bao; Zhongmin Ma; John Turk
Journal:  Biochemistry       Date:  2003-12-02       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.